Welcome to our Symprove for Professionals website
Please confirm you are a healthcare professional to access this site.
About Symprove
Symprove is a unique, water-based probiotic with four strains of live & active bacteria, proven to reach the gut alive & support the microbiome.*(1,2)
University College London School of Pharmacy investigated a range of probiotics in an in vitro model simulating human gut conditions.
Symprove’s bacteria were shown to arrive, survive and thrive in the gut.(1)
Hear from Professor Simon Gaisford, Professor of Pharmaceuticals at University College London.
How Symprove works
Find out how Symprove arrives in the gut in a live state & supports a diverse microbiome.
Dr Sarah Jarvis MBE, FRCGP
Practicing GP, Clinical Consultant for patient.info and Medical broadcaster
"In order to be effective, probiotics need to 'arrive, survive and thrive’"
Symprove bacteria
Symprove contains four live strains of bacteria:*
- Lacticaseibacillus rhamnosus NCIMB 30174
- Enterococcus faecium NCIMB 30176
- Lactobacillus acidophilus NCIMB 30175
- Lactiplantibacillus plantarum NCIMB 30173
The Lactiplantibacillus species
- Symprove contains Lacticaseibacillus rhamnosus, Lactobacillus acidophilus & Lactiplantibacillus plantarum
- Various types of these bacteria are found in the human gastrointestinal tract. Rhamnosus, acidophilus
and plantarum all have a history of being used in food(4) - EFSA has added these three species to the Qualified Presumption of Safety list (3)
Enterococcus faecium
- Symprove contains Enterococcus faecium
- These bacteria are commonly found in human microbiomes & have a history of being used in food (3)
- The strain used in Symprove is fully characterised & has been subject to whole genome sequencing by the NCIMB, to confirm identity and provide safety data, which differentiate it from other strains (4)
Symprove safety
- >20,000 people take Symprove every month
- No serious adverse events have been recorded since commercial sales began in 2010 (4)
- Clinical studies in humans, including those with pre-existing conditions, have been approved by
ethics committees and no serious adverse events recorded in those trials (4)
REFERENCES
1. Fredua-Agyeman M and Gaisford S. Comparative survival of commercial probiotic formulations: Tests in biorelevant gastric fluids and real-time measurements using microcalorimetry. Beneficial Microbes 2015;6(1):141-151.
2. Moens F, et al. A four-strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro. Int J Pharm 2019;555:1-10.
3. Goldstein E, et al. Lactobacillus Species: Taxonomic Complexity and Controversial Susceptibilities. Clin Infect Dis 2015;60(2):S98-S107.
4. Gelsomino R, et al. Source of enterococci in a farmhouse raw-milk cheese. Appl Environ Microbiol 2002;68(7):3560-3565.
FOOTNOTES
*Symprove contains four live strains of bacteria: Lacticaseibacillus rhamnosus NCIMB 30174, Enterococcus faecium NCIMB 30176, Lactobacillus acidophilus NCIMB 30175, Lactiplantibacillus plantarum NCIMB 30173. The bacteria in Symprove have all been independently characterised by the NCIMB (The National Collection of Industrial and Marine Bacteria) using the latest DNA sequencing and mass spectrometry techniques. These methods have enabled characterisation of the genera, species and strains.
Symprove delivers 10 billion CFUs (colony-forming units) per 70ml cup, consistent with amount used in human clinical research trials.